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Is There a Rationale for Changing the Established 
Fractionation Regimens in the Near Future?
Malignant tumor cells and the surrounding healthy tissues dif-
fer with regard to their radiation sensitivity. The cells of normal 
healthy tissues are able to recover from sublethal radiation damage, 
whereas tumor cells show limited repair. These differences have 
been investigated intensively and have resulted in distinctive radio-
therapeutic treatment regimens in which the daily fraction dose, 
TD, and adherent treatment schedules have been established [6]. 
Dose effectiveness in modern radiotherapy is described with the 
linear-quadratic model (α/β model), predicting radiobiologically 
equivalent (isoeffective) doses. The α/β value of the linear-quad-
ratic model describes the sensitivity of healthy tissue and tumor 
cells depending on fractionation and TD. The fractionation sensi-
tivity of any tissue is characterized by its α/β value; the α/β value is 
a mathematically calculated term derived from the dose-effect 
curve of the tissue, given in units of Gray (Gy). Generally, the α/β 
values of healthy tissues for late reactions are low (in the range of 
2–3 Gy). In contrast, tumors and early reacting tissues have much 
higher α/β values in the range of 10 Gy or more [7]. In order to 
protect the healthy tissue from late radiation effects, irradiation 
should therefore be administered at low single doses of 1.2–2 Gy. 
The linear-quadratic model has been confirmed in a variety of 
randomized studies, and it is a proven radiobiological fact that the 
greatest therapeutic window with regard to both local tumor con-
trol and late tissue effects is achieved if low doses per fraction are 
administered. However, the dogma that all tumors have high α/β 
values has been challenged over the past years. Over the past dec-
ade, growing evidence has accumulated that at least some cancers 
may have exceptionally low α/β values. This has so far been proven 
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Summary
Hypofractionated radiotherapy for breast cancer is be-
coming increasingly important. The scientific back-
ground of this development as well as the introduction 
of the simultaneous integrated boost to the primary 
tumor region in this context are discussed here.
© 2015 S. Karger GmbH, Freiburg
Introduction
Current standard whole breast irradiation (WBI) in breast-con-
serving concepts consists of a total dose (TD) of 50 Gy delivered in 
25 daily fractions over a period of approximately 35 days. Alterna-
tively, 50.4 Gy are applied using a daily dose of 1.8 Gy. An addi-
tional boost to the primary tumor region at a TD of 12–16 Gy is 
indicated in the majority of patients, resulting in an overall treat-
ment period of up to 47 days [1–4]. Impressive data of more than 
10,000 women in 17 randomized trials with a 15-year follow-up 
confirm a risk reduction of ipsilateral breast recurrences by a factor 
of at least 3–4 [5]. This translates into a risk reduction of about 3% 
for breast cancer deaths in node-negative patients and about 8% in 
node-positive patients. Moreover, there is plenty of experience 
concerning treatment-related acute and late toxicity accompanied 
by excellent cosmetic results [1].
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for prostate cancer with an α/β value of about 1.5 Gy. If the α/β 
value of the tumor is below the α/β value of late-reacting surround-
ing tissue, treatment with higher doses per fraction is, from a theo-
retical point of view, advantageous. Therefore, hypofractionation 
has a well-defined theoretical basis in prostate cancer, and the re-
sults of completed and ongoing randomized studies support the 
notion that at least moderate hypofractionation is feasible in pros-
tate cancer. Moreover, recent data suggest that prostate cancer is 
probably not the only exception and that some form of hypofrac-
tionation may be feasible in certain other cancer entities [8].
Why Was Hypofractionation Introduced in Breast 
Cancer?
The hypofractionation studies in breast cancer were started at a 
time when the data on low α/β values in tumors were not yet avail-
able. The aim of these breast cancer studies was a more pragmatic 
one, mainly to decrease the number of visits to the radiotherapy 
department and to shorten overall treatment time, thereby making 
adjuvant radiotherapy more convenient for patients. These studies 
were conducted in countries with centralized radiotherapy struc-
tures and long travel distances. It was assumed that a relevant sub-
group of patients who were candidates for breast-conserving treat-
ment did in fact choose mastectomy as primary treatment due to 
the inability to withstand a 6–8-week course of radiotherapy. 
Therefore, studies were started in the 1990s evaluating an overall 
shortened treatment time to increase acceptance of adjuvant radio-
therapy and reduce costs.
Surprisingly, the latest data from these studies assume an α/β 
value for breast cancer of 3–3.5 Gy which is similar to that of the 
surrounding normal healthy tissue [9, 10]. This would mean that 
fraction size can be changed within a relatively broad range with-
out negative impact on tumor control and late radiation sequelae. 
Although not expected at the beginning of these trials, the data 
form a stable theoretical basis for the use of moderate hypofrac-
tionation in breast cancer. 
Which Studies Support the Effectiveness and 
Safety of Hypofractionation in Breast Cancer?
So far, 4 randomized trials have examined a hypofractionated 
schedule as compared to the standard 5-week fractionation sched-
ule for adjuvant WBI. 
The UK START pilot trial assessed dose schedules using either 3 
Gy/fraction up to a TD of 39 Gy, or 3.3 Gy/fraction with a TD of 
42.9 Gy (13 fractions) compared to the standard regimen of 2 Gy/
fraction and a TD of 50 Gy [11, 12]. The following START-A ran-
domized 2,236 patients to 1 of 3 treatment arms: 3 Gy/fraction 
(every second day) to a TD of 39 Gy, 3.2 Gy to a TD of 41.6 Gy, and 
standard normofractionation [13]. START-B compared the stan-
dard schedule with a daily hypofractionated schedule using 40 Gy 
with a fraction size of 2.66 Gy [14]. It should be noted that in both 
START trials 61% of all patients finally received a sequential boost 
with 10 Gy (2 Gy/fraction). The boost was always administered 
after hypofractionated breast irradiation.
After 10-years, all treatment concepts showed equivalent out-
comes for hypofractionated radiotherapy compared to the tradi-
tional schedule, favoring the use of 40 Gy in 15 fractions with a low 
local recurrence rate of 5.6% [9]. All 3 trials included women with 
operable T1–3 N0–1 M0 invasive breast cancer and mostly small or 
medium breast size. 
Another trial reproduced these results independently: The On-
tario Clinical Oncology Group randomly assigned 1,234 patients to 
standard WBI or to 42.5 Gy in 16 fractions within 22 days [15]. 
1,234 women with invasive breast cancer (< 5 cm, no T3–4, nega-
tive margins, node-negative) and without multicentric disease, 
large breast size, and bilateral breast cancer were included. After 10 
years, the risk of recurrence was 6.7% in the standard group and 
6.2% in the hypofractionated group. Cosmetic outcome was re-
ported as good or excellent with 71.3% in the standard group and 
69.8% in the hypofractionated group. These studies built the clini-
cal basis for an α/β value of breast cancer in the range of 3–3.5 Gy, 
similar to that of the surrounding healthy tissues (table 1).
Ongoing Controversies Concerning the  
Hypofractionated Treatment of Breast Cancer
High-Risk Features
The majority of patients in the above mentioned trials had es-
trogen receptor-positive and HER2-negative tumors. It is well 
known that patients with high-grade tumors have a higher risk of 
local recurrence after radiation. It is therefore questionable 
whether hypofractionated WBI is suitable for all patients [1]. The 
10-year update of the START trials including 1,272 women with 
grade 3 breast cancer showed no difference between hypo- and 
normofractionation in terms of local recurrence in this group [9], 
whereas the Ontario trial documented a significantly higher local 
failure rate in the hypofractionation arm [15], which was somehow 
considered a statistical fluke. In contrast to the Ontario trial, a se-
quential boost to the primary tumor site was allowed in the START 
trials, which may also be a possible explanation for the different 
treatment results in the high-risk group. Recently, the Ontario 
group published the results of their analysis of tumor factors pre-
dictive for response to hypofractionated versus normofractionated 
radiotherapy. They stated that tumor grade, histological subtype, 
and hypoxia did not predict for hypofractionation response, proof-
ing that hypofractionation can be safely administered in all breast 
cancer patients [16]. 
Young Age
The 2011 ASTRO consensus did not recommend hypofraction-
ation in women < 50 years of age [17] as younger women have a 
higher risk of local recurrence compared with older patients, and 
only few younger patients were randomized in those studies at this 
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time. However, of the 4 major trials, only the Ontario study strati-
fied by age and detected no significant differences in ipsilateral 
tumor recurrence, although no boost was applied [15]. The 10-year 
update of the START trials included 1,398 women < 50 years of age 
and demonstrated the effectiveness of hypofractionation in 
younger patients, even showing a trend towards an improved effect 
of hypofractionation in this cohort [9].
Regional Nodal Irradiation
There is only limited experience with hypofractionated regional 
irradiation due to the small number of women with regional radio-
therapy recruited in the reported studies. The safety of the investi-
gated fractionation schemes in view of brachial plexopathy is still 
under investigation. In the START trials, the only reported plex-
opathy occurred with the 41.6 Gy fractionation schedule [9].
Cardiotoxicity
Late cardiac side effects of hypofractionated radiotherapy have 
only been evaluated to a maximum follow-up of 10 years. Since 
most radiotherapy-associated cardiac side effects occur after 15 
years or more, currently available results must be assessed with 
caution, especially in women with a long life expectancy and an 
unhealthy lifestyle. However, no significant cardiotoxicity has been 
observed in modern normofractionated radiotherapy for breast 
cancer with current radiotherapy techniques making it now safer 
than in the past [18]. Recently, Chan et al. [19] reported a 15-year 
Table 1. Study data on hypofractionation in breast cancer treatment [25]
10-year event RMH/GOC START A START B Canadian




50 12.1 0.027 50  6.7 NS 50  3.8 NS 50  7.4 NS
42.9  9.6 41.6  5.6 50  5.2 42.5  7.5
39 14.8 39  8.1
Distant  
relapse
NR 50 14.7 NS 50 16.0 0.014 NR




NR 50 19.8 NS 50 19.2 0.042 50 15.6 NS







50 18.1 0.065 50  7.2 – 50  5.8 0.032 42.5 69.8 NS
42.9 18.0 41.6  7.1 0.99 40  4.2 50 71.3
39 12.0 39  3.0 0.003
breast edema
50 13.8 0.004 50 13.5 – 50  9.0 0.001
42.9 21.5 41.6 11.8 0.24 40  5.1







50  1.9 50  2.1 42.5  2.7 NS




grade 3  
subcutaneous  
tissue
50  1.2 50  1.7 42.5  3.6 NS
41.6  1.1 40  1.7 50  2.5
39  1.0
NR = Not reported; NS = not significant; RMH/GOC = Royal Marsden Hospital/Gloucester Oncology Center; START A/B = Standardization of Breast Radiotherapy 
Trial A/B.
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follow-up of cardiac injury, comparing hypofractionation versus 
normofractionation in left-sided early-stage breast cancer patients. 
In 5,334 patients receiving breast or chest wall irradiation, no sta-
tistically significant difference in cardiac mortality was detected.
Implementation of a Simultaneous Integrated Boost 
in Hypofractionated Radiotherapy of Breast Cancer 
A boost to the primary tumor site improves local control in all 
age groups. In R0-resected patients, the local recurrence rate is re-
duced by 4–6.2% within 10 years [20]. To maintain this important 
treatment effect in hypofractionated WBI without altering the 
overall shortened treatment time, 4 studies have been conducted so 
far in which a simultaneous integrated boost (SIB) was introduced. 
Scorsetti et al. [21] enrolled 50 women to be treated with an SIB-
VMAT (volumetric-modulated arc therapy) approach, applying 
doses of 40.5 Gy to the whole breast and 48 Gy to the primary 
tumor bed in 15 fractions. They observed 1 grade 3 and 32 grade 1 
skin toxicities, with the latter resolving within 3 weeks of treatment 
completion. No significant changes in cosmetic outcome were ob-
served 3 and 6 months after radiotherapy. Another protocol deliv-
ering 40.5 Gy to the breast and 45 Gy as an SIB in 15 fractions over 
19 days was investigated by Chada et al. [22]. The 5-year disease-
free survival was 97%, based on a median follow-up of 3.5 years. 
Acute and late toxicity were low without any grade 3 or 4 skin tox-
icity after 2 years. A randomized trial by van Parijs et al. [23] com-
pared conventional radiotherapy to hypofractionated tomotherapy 
with 2.8 Gy/fraction to the whole breast and an SIB of 0.6 Gy/frac-
tion in 15 fractions. The primary purpose of this study was to eval-
uate whether tomotherapy reduces heart and lung toxicity in this 
setting. They demonstrated a slight trend in favor of tomotherapy, 
stating that short-course treatment with SIB is feasible with no se-
vere toxicity. The largest prospective investigation so far, a German 
multicenter phase II study, treated 141 patients with 40 Gy to the 
whole breast and an SIB of 48 Gy in 16 fractions. The regimen was 
well tolerated with no grade 3 or 4 adverse events [24]. According 
to this trial, hypofractionation with SIB seems to be safe and feasi-
ble with unchanged quality of life, even though long-term follow-
up is still missing. The new prospective multicenter 2-arm phase 
III German HYPOSIB trial will provide data on hypofractionated 
irradiation with SIB with an overall very much shortened treat-
ment time compared to standard radiotherapy. This non-inferior-
ity trial is designed to recruit 1,162 patients in each arm. The study 
will randomize all patients with histologically confirmed unilateral 
invasive breast cancer after breast-conserving surgery with an indi-
cation for a boost. 
Conclusion
Current clinical results of hypofractionated WBI support its in-
troduction into clinical routine in the near future. Hypofractiona-
tion offers an alternative to standard fractionation regimens at least 
in a subset of patients. There is now a clear radiobiological basis for 
the use of moderate hypofractionation with a decrease in the num-
ber of fractions by about 50%; extreme hypofractionation (e.g. less 
than 10 fractions) or extremely reduced treatment times (e.g. less 
than 3 weeks) should, however, be restricted to clinical trials. 
Moreover, there is limited data on potentially different effects of 
hypofractionation in subgroups, and it is unclear whether the ef-
fects of standard fractionation and hypofractionation are really 
identical in all tumor subtypes. Delivery of a tumor bed boost in 
the form of an SIB seems to be safe, feasible, and effective while 
further reducing the overall treatment time without compromising 
established excellent overall results. The new HYPOSIB trial will 
clarify the question of simultaneous boost application and hypof-
ractionation in breast cancer on the basis of a high number of pa-
tients. All German radiotherapy facilities are encouraged to partici-
pate in the HYPOSIB trial as the study subject is a highly relevant 
key issue in the development of modern radiotherapy of breast 
cancer in Germany.
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